What's in Mesoblast, Ltd.'s pipeline?

Mesoblast, Ltd. has 6 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 4 in Phase 2, 1 in Phase 1.

Which companies overlap with Mesoblast, Ltd.'s portfolio?

Top competitors by shared drug class: Anterogen Co., Ltd., Cell Biopeutics Resources Sdn Bhd, Kang Stem Biotech Co., Ltd., Medipost, Inc., Pharmicell Co., Ltd..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/mesoblast-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

Mesoblast, Ltd. — Portfolio Competitive Intelligence Brief

Mesoblast, Ltd. pipeline: 0 marketed, 0 filed, 1 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 4 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Rexlemestrocel-L + HA Mixture	Rexlemestrocel-L + HA Mixture	phase 3	Allogeneic mesenchymal stem cell therapy		Regenerative Medicine / Orthopedics

Therapeutic area mix

Regenerative Medicine / Orthopedics · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Anterogen Co., Ltd. · 1 shared drug class
Cell Biopeutics Resources Sdn Bhd · 1 shared drug class
Kang Stem Biotech Co., Ltd. · 1 shared drug class
Medipost, Inc. · 1 shared drug class
Pharmicell Co., Ltd. · 1 shared drug class
Tigenix S.A.U. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Mesoblast, Ltd.:

Cite this brief

Drug Landscape (2026). Mesoblast, Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/mesoblast-ltd. Accessed 2026-05-14.